EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients

Matteo Domenico Marsiglia iD, Silvia Bianchi iD, Francesca Bai iD, Camilla Tincati iD, Emerenziana Ottaviano iD, Silvia Ancona iD, Giulia Marchetti iD, Elisa Borghi iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0321356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Matteo Domenico Marsiglia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Università degli Studi di Milano, Milano, Italy. Hauptthemen laut MEDLINE: SARS-CoV-2, RNA, Viral, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) have been shown to have clinical benefits in treating high-risk patients with mild-moderate COVID-19. SARS-CoV-2 RNA in serum (RNAemia), is usually associated with severe disease and deaths. This study evaluates real-life data on the effectiveness of mAbs therapies against SARS-CoV-2 infections by different viral variants, particularly in the presence of RNAemia, focusing on clinical outcomes.

Methods

From March 2021 to May 2022, high-risk patients with PCR-confirmed mild-moderate COVID-19 were enrolled at the Clinic of Infectious Diseases, San Paolo Hospital in Milan. Patients received Bamlanivimab/Bamlanivimab + Etesevimab/Casirivimab + Imdevimab/Sotrovimab based on Agenzia Italiana del Farmaco (AIFA) guidelines and prevalent SARS-CoV-2 variants. Nasopharyngeal swabs (NPS) and plasma samples were collected at infusion (t0) and after 7 days (t1). NPS viral loads and RNAemia were quantified using RT-qPCR, and variant typing was conducted. Clinical outcomes were evaluated, including time to symptom resolution and adverse effects.

Results

Among 176 enrolled patients, treatment efficacy was observed in 96.6% with a median time to symptom resolution of 12 days (IQR 10–19). Viral load significantly decreased in both NPS and plasma by day 7 post-treatment (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2RNA, ViralCOVID-19COVID-19 Drug TreatmentAntibodies, NeutralizingAntibodies, MonoclonalHumansMaleFemaleMiddle AgedAgedAntibodies, Monoclonal, HumanizedTreatment OutcomeAdultViral LoadAntiviral Agents

Substanzen

RNA, ViralAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingbamlanivimabAntibodies, MonoclonaletesevimabimdevimabAntiviral Agentscasirivimab

Autor:innen und Institutionen

  • Department of Health Sciences, Università degli Studi di Milano, Milano, Italy.
  • Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, Università degli Studi di Milano, Milano, Italy.

ORCID-Profile: Matteo Domenico Marsiglia, Silvia Bianchi, Francesca Bai, Camilla Tincati, Emerenziana Ottaviano, Silvia Ancona, Giulia Marchetti, Elisa Borghi

Zitieren

APA

Marsiglia, M. D., Bianchi, S., Bai, F., Tincati, C., Ottaviano, E., Ancona, S., Marchetti, G., & Borghi, E. (2025). Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients. PLOS One. https://doi.org/10.1371/journal.pone.0321356

Vancouver

Marsiglia MD, Bianchi S, Bai F, Tincati C, Ottaviano E, Ancona S, et al. Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients. PLOS One. 2025. doi:10.1371/journal.pone.0321356

BibTeX
@article{Marsiglia2025,
  author = {Marsiglia, Matteo Domenico and Bianchi, Silvia and Bai, Francesca and Tincati, Camilla and Ottaviano, Emerenziana and Ancona, Silvia and Marchetti, Giulia and Borghi, Elisa},
  title = {Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0321356}
}
Kostenlos starten →